Cipla petitions Indian Government to revoke Onbrez patents

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

Cipla petitions Indian Government to revoke Onbrez patents

Generics/News | Posted 21/11/2014 0 Post your comment

India-based generics maker Cipla has asked the Indian Government to revoke five patents held by Swiss firm Novartis for its respiratory drug Onbrez (indacaterol), after launching its own generic version of the drug.

Cipla has asked the Indian Government’s Department of Industrial Policy & Promotion (DIPP) to revoke five of the patents that Novartis holds in India relating to Onbrez, citing a need for public health access and that the patent holder Novartis does not manufacture the drug in India.

The originator product is 400% more expensive than Cipla’s generic version, which is marketed under the Unibrez brand and costs only Rs 130 per strip of 10 tablets. Novartis only brought in 53,844 units of the drug in 2013, serving 4,500 patients annually. This, according to Cipla is a ‘negligible quantity’ and is leading to a shortage of supplies in the Indian market. Cipla, on the other hand, ‘believes that it has the potential to manufacture adequate quantities of the drug’.

Cipla’s filing regarding the Novartis patents was made under Section 66 of the Indian Patents Act, which grants the Indian Government the power to revoke a patent in the public interest.

If India does overturn the Novartis patents, it would not be the first time that the country has done so. Novartis already challenged India’s patent laws back in 2006 when it failed to receive patent protection for its blockbuster cancer medication Glivec (imatinib mesylate) [1]. Cipla also won in a patent infringement case filed by Roche back in 2012 over Cipla’s version of its cancer drug Tarceva (erlotinib) [2].

Related articles
India’s patent office at odds with Big Pharma

Bayer loses Nexavar compulsory licence appeal

References
1. GaBI Online - Generics and Biosimilars Initiative. India’s patent laws coming under repeated challenges [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Nov 21]. Available from: www.gabionline.net/Policies-Legislation/India-s-patent-laws-coming-under-repeated-challenges
2. GaBI Online - Generics and Biosimilars Initiative. India patent laws under close scrutiny [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Nov 21]. Available from: www.gabionline.net/Policies-Legislation/India-patent-laws-under-close-scrutiny

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: Cipla